BofA raises Denali Therapeutics target to 34 on BLA plans
DNLI Stock | USD 24.69 0.47 1.94% |
Under 70 percent of all Denali Therapeutics' traders are curious in acquiring. The analysis of the overall investor sentiment regarding Denali Therapeutics suggests that a large number of traders are confidant. Denali Therapeutics' investing sentiment shows overall attitude of investors towards Denali Therapeutics.
Denali |
BofA raises Denali Therapeutics target to 34 on BLA plans
Read at investing.com
Denali Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Denali Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Denali Therapeutics Fundamental Analysis
We analyze Denali Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Denali Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Denali Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Denali Therapeutics stock to make a market-neutral strategy. Peer analysis of Denali Therapeutics could also be used in its relative valuation, which is a method of valuing Denali Therapeutics by comparing valuation metrics with similar companies.
Peers
Denali Therapeutics Related Equities
APLS | Apellis Pharmaceuticals | 10.88 | ||||
SWTX | SpringWorks Therapeutics | 7.49 | ||||
HOWL | Werewolf Therapeutics | 6.74 | ||||
ASND | Ascendis Pharma | 5.85 | ||||
AKRO | Akero Therapeutics | 4.90 | ||||
BDTX | Black Diamond | 4.53 | ||||
LEGN | Legend Biotech | 2.99 | ||||
DAWN | Day One | 2.85 | ||||
GLUE | Monte Rosa | 1.68 | ||||
RNA | Avidity Biosciences | 1.62 | ||||
STOK | Stoke Therapeutics | 1.42 | ||||
DSGN | Design Therapeutics | 0.90 | ||||
PCVX | Vaxcyte | 0.17 | ||||
RVMD | Revolution Medicines | 0.05 | ||||
TVTX | Travere Therapeutics | 0.05 | ||||
IKNA | Ikena Oncology | 1.16 | ||||
BGNE | BeiGene | 2.08 | ||||
FDMT | 4D Molecular | 2.50 | ||||
BPMC | Blueprint Medicines | 2.56 |
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |